TR200002894T2 - L-Carnitine or an alkanoyl L-Carnitine and composition containing NADH and / or NADPH - Google Patents

L-Carnitine or an alkanoyl L-Carnitine and composition containing NADH and / or NADPH

Info

Publication number
TR200002894T2
TR200002894T2 TR2000/02894T TR200002894T TR200002894T2 TR 200002894 T2 TR200002894 T2 TR 200002894T2 TR 2000/02894 T TR2000/02894 T TR 2000/02894T TR 200002894 T TR200002894 T TR 200002894T TR 200002894 T2 TR200002894 T2 TR 200002894T2
Authority
TR
Turkey
Prior art keywords
carnitine
nadph
alkanoyl
composition containing
containing nadh
Prior art date
Application number
TR2000/02894T
Other languages
Turkish (tr)
Inventor
Cavazza Claudio
Original Assignee
Sigma-Tau Healhscience S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Healhscience S.P.A. filed Critical Sigma-Tau Healhscience S.P.A.
Publication of TR200002894T2 publication Critical patent/TR200002894T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

L-karnitin veya bir alkanoil L-karnitin veya bunlarin farmasötik olarak kabul edilebilir tuzu ve NADH ve/veya NADPH içeren, kronik yorgunluk sendromu ve Parkinson hastaliginin tedavisi için bir ilaç olarak ve yorucu fiziksel egzersizde bulunan kisiler veya kuvvetsiz denekler için bir diyet yardimcisi olarak yararli bir kompozisyon açiklanmaktadir.Useful as a medicine for the treatment of chronic fatigue syndrome and Parkinson's disease, including L-carnitine or an alkanoyl L-carnitine or their pharmaceutically acceptable salt and NADH and / or NADPH, and as a dietary aid for individuals or weak subjects in strenuous physical exercise. a composition is described.

TR2000/02894T 1998-04-17 1999-04-14 L-Carnitine or an alkanoyl L-Carnitine and composition containing NADH and / or NADPH TR200002894T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT98RM000238A IT1299161B1 (en) 1998-04-17 1998-04-17 COMPOSITION INCLUDING L-CARNITINE OR AN ALCANOYL L-CARNITINE AND NADH AND / OR NADPH

Publications (1)

Publication Number Publication Date
TR200002894T2 true TR200002894T2 (en) 2001-01-22

Family

ID=11405812

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02894T TR200002894T2 (en) 1998-04-17 1999-04-14 L-Carnitine or an alkanoyl L-Carnitine and composition containing NADH and / or NADPH

Country Status (17)

Country Link
EP (1) EP1071424A1 (en)
JP (1) JP2002512191A (en)
KR (1) KR20010042765A (en)
CN (1) CN1299283A (en)
AU (1) AU750645B2 (en)
BR (1) BR9909712A (en)
CA (1) CA2328331A1 (en)
EE (1) EE200000601A (en)
HU (1) HUP0101914A3 (en)
IL (1) IL139014A0 (en)
IS (1) IS5663A (en)
IT (1) IT1299161B1 (en)
NO (1) NO20005128L (en)
PL (1) PL343482A1 (en)
SK (1) SK15442000A3 (en)
TR (1) TR200002894T2 (en)
WO (1) WO1999053921A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252309B2 (en) 2000-04-04 2012-08-28 Sigma-Tau Industrie Farmaceutiche Riunite Spa Dietary supplement energy-providing to skeletal muscles
DE10326822A1 (en) * 2003-06-11 2005-01-05 Herzpharma Vita-Check Diagnosegeräte GmbH Dietary supplement, e.g. for increasing general performance, concentration and endurance, comprises NADH, L-carnitine, coenzyme Q10, L-carnosine, succinic acid, ascorbic acid and bioflavonoids
CA2686905C (en) * 2007-05-11 2015-07-07 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of cosmetic active ingredients
US20120214870A1 (en) * 2009-08-31 2012-08-23 University Of South Australia Methods for diagnosis and treatment of chronic fatigue syndrome
CN104306390A (en) * 2014-10-23 2015-01-28 苏州人本药业有限公司 Application of reduced coenzyme II
CN104840479A (en) * 2015-02-17 2015-08-19 苏州人本药业有限公司 Application of NADPH in preparation of drugs used for treating heart diseases
WO2019119445A1 (en) * 2017-12-22 2019-06-27 邦泰生物工程(深圳)有限公司 Nadh compound, and formulation and application thereof
JP7130844B2 (en) 2018-04-20 2022-09-05 パコトレード アクチェンゲゼルシャフト Apparatus for shredding frozen food provided in blocks
CN109105702A (en) * 2018-08-30 2019-01-01 泓博元生命科技（深圳）有限公司 A kind of preparation method of composition containing NADH, application and energy extender
CN109170907A (en) * 2018-08-30 2019-01-11 泓博元生命科技（深圳）有限公司 A kind of preparation method of composition containing NMN, application and sports drink
CA3115743A1 (en) * 2018-10-10 2020-04-16 So Ngor Sally LEUNG Health-care product composition for enriching asthenic disease, preparation method therefor and use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054698A (en) * 1964-12-04
US5292538A (en) * 1992-07-22 1994-03-08 Metagenics, Inc. Improved sustained energy and anabolic composition and method of making
DE4335454A1 (en) * 1993-10-19 1995-04-20 Schleicher Peter Geriatric medical composition
JPH09110708A (en) * 1995-08-11 1997-04-28 Taisho Pharmaceut Co Ltd Pharmaceutical preparation comprising crude drug for nourishment and robust
JPH0959161A (en) * 1995-08-23 1997-03-04 Taisho Pharmaceut Co Ltd Fatigue improving composition
IT1277953B1 (en) * 1995-12-21 1997-11-12 Sigma Tau Ind Farmaceuti PHARMACEUTICAL COMPOSITION CONTAINING L-CARNITINE OR AN ALCANOYL L-CARNITINE AND A 3-OMEGA SERIES POLYUNSATURED ACID USEFUL
IT1283951B1 (en) * 1996-03-15 1998-05-07 Mendes Srl USE OF ACETYL L-CARNITINE OR ITS PHARMACOLOGICALLY ACCEPTABLE SALTS FOR THERAPEUTIC TREATMENT OR PROPHYLAXIS OF
US5712259A (en) * 1996-04-22 1998-01-27 Birkmayer Pharmaceuticals NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
JPH10175856A (en) * 1996-10-14 1998-06-30 Taisho Pharmaceut Co Ltd Fatigue relieving agent

Also Published As

Publication number Publication date
NO20005128D0 (en) 2000-10-12
KR20010042765A (en) 2001-05-25
IT1299161B1 (en) 2000-02-29
CN1299283A (en) 2001-06-13
IS5663A (en) 2000-10-13
WO1999053921A1 (en) 1999-10-28
JP2002512191A (en) 2002-04-23
NO20005128L (en) 2000-12-18
ITRM980238A0 (en) 1998-04-17
IL139014A0 (en) 2001-11-25
EP1071424A1 (en) 2001-01-31
HUP0101914A2 (en) 2002-03-28
CA2328331A1 (en) 1999-10-28
ITRM980238A1 (en) 1999-10-17
HUP0101914A3 (en) 2002-12-28
AU750645B2 (en) 2002-07-25
BR9909712A (en) 2000-12-26
PL343482A1 (en) 2001-08-27
AU3442899A (en) 1999-11-08
EE200000601A (en) 2002-04-15
SK15442000A3 (en) 2001-06-11

Similar Documents

Publication Publication Date Title
AR052921A1 (en) USE OF RANOLAZINE FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION
BR9714427A (en) Apparatus and method for noninvasively measuring cardiac output
TR200002894T2 (en) L-Carnitine or an alkanoyl L-Carnitine and composition containing NADH and / or NADPH
HK1041636A1 (en) Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases
WO2003013549A3 (en) Formulation containing (lyso-) phosphatidylserine for the prevention and treatment of stress states in warm-blooded animals
WO2001056402A3 (en) Alpha lipoic acid based food supplement to increase lean muscle mass and strength
BR0309855A (en) Carbamate substituted pyrazolpyridines
BR9710585A (en) Composition for enteral administration, process to improve the physical resistance or athletic performance of a mammal, to increase the concentration of protein, fat-free body mass or muscle mass in a mammal, to decrease the deposition of body fat for a given caloric intake and to increase the loss of body fat in a mammal, to treat the catabolic effects of disease in a mammal, to improve a mammal's physical endurance or athletic performance, and to increase the mass of a mammal's lean body and decrease the fat deposition
ZA9426B (en) Use of riluzole for the treatment of Parkinson's Disease and Parkinsonian Syndromes
MX9402938A (en) THERAPEUTIC COMPOSITION COMPRISING NICOTINAMIDE-ADENINE-DINUCLEOTIDE AND NICOTINAMIDE-ADENINE-PHOSPHATE-DINUCLEOTIDE, STABLE, INGERIBLE AND ABSORBABLE.
CY1108629T1 (en) Combination ET 743 with 5 Fluorouracil Pre-medicines for the therapeutic treatment of the heart
PT1163904E (en) COMPOSITION FOR THE PREVENTION OF SMOOTH MUSCLE DISEASES, COMPOSING ASCORBATE, ARGININE AND MAGNESIUM
HUP9700806A2 (en) Matrix tablet allowing the prolonged release of the sodium salt of tianeptine and process for the preparation thereof
PE20001325A1 (en) CERIVASTATIN AND FIBRATES COMBINATION
IT1295408B1 (en) ASSOCIATION OF L-CARNITINE AND ALCANOYL L-CARNITINE FOR THE TREATMENT OF ALCOHOLISM
BRPI0409699A (en) methods of inducing the diuretic effect, inducing, maintaining or restoring the diuretic effect of a non-adenosine modifying diuretic, maintaining, restoring or improving renal function in a patient, inducing diuresis, preventing the onset of renal impairment in a patient with fluid or CHF overload, treating CHF patients and improving overall health outcomes, pharmaceutical composition and uses
MX9703810A (en) Medicament comprising a carnitine derivative to treat alzheimer disease in patients with premature onset.
EP1393738A4 (en) Drugs for diabetes
BR9813856A (en) Processes for the treatment of a patient suffering from premenstrual syndrome, depression, anemia, migraines or eating disorders and to increase the level of serotonin in a human with a reduced level of blood flow and composition
BR0108261A (en) Use of mirtazapine, method of treating a sleep disorder in an individual, and patient kit for the treatment of sleep disorders
ES1052893U (en) Balancing instrument gymnastics. (Machine-translation by Google Translate, not legally binding)
CN2836786Y (en) The vola acupressure probe
Heikkinen et al. Growing Older-Staying Well: Ageing and physical activity in everyday life
HUP9701606A2 (en) Use of sulbutiamine to obtain pharmaceutical compositions useful in the treatment of certain psychomotor and psychointellectual disorders
CA2304899A1 (en) New use of selective serotonin reuptake inhibitors for treatment of human patients with chest pain of non-cardiac origin or with gastro-esophageal reflux disease